Published in Hepatology on December 01, 2003
Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest (2009) 3.80
Infected site-restricted Foxp3+ natural regulatory T cells are specific for microbial antigens. J Exp Med (2006) 3.22
Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology (2008) 2.95
T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol (2005) 2.58
Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog (2009) 2.57
Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology (2005) 2.52
FoxP3+CD4+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2-/-gammaC-/- mice in vivo. Blood (2008) 2.31
Tregs control the development of symptomatic West Nile virus infection in humans and mice. J Clin Invest (2009) 2.18
Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol (2005) 2.14
A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology (2011) 2.06
Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med (2013) 2.02
Heterologous T cell immunity in severe hepatitis C virus infection. J Exp Med (2005) 1.68
Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Invest (2006) 1.66
Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection. J Virol (2008) 1.63
Natural regulatory T cells and persistent viral infection. J Virol (2007) 1.62
Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J Virol (2005) 1.60
The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design. Gut (2015) 1.51
Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation. Immunol Rev (2014) 1.38
Foxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C. Blood (2006) 1.25
Homeostasis and function of regulatory T cells in HIV/SIV infection. J Virol (2012) 1.23
Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis. J Hepatol (2008) 1.22
Differential dysfunction in dendritic cell subsets during chronic HCV infection. Clin Immunol (2007) 1.17
Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines (2009) 1.16
Acute hepatitis C virus infection: a chronic problem. Hepatology (2008) 1.15
Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor beta that can suppress HCV-specific T-cell responses. J Virol (2007) 1.13
FoxP3 enhances HIV-1 gene expression by modulating NFkappaB occupancy at the long terminal repeat in human T cells. J Biol Chem (2007) 1.13
Regulatory T cells in human disease and their potential for therapeutic manipulation. Immunology (2006) 1.12
Foxp3 and Treg cells in HIV-1 infection and immuno-pathogenesis. Immunol Res (2008) 1.11
Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infection. PLoS Pathog (2009) 1.08
PD-1 modulates regulatory T cells and suppresses T-cell responses in HCV-associated lymphoma. Immunol Cell Biol (2010) 1.07
Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. J Virol (2008) 1.05
CD137 costimulation of CD8+ T cells confers resistance to suppression by virus-induced regulatory T cells. J Immunol (2008) 1.05
The role of virus-induced regulatory T cells in immunopathology. Springer Semin Immunopathol (2006) 1.05
Level, phenotype and activation status of CD4+FoxP3+ regulatory T cells in patients chronically infected with human immunodeficiency virus and/or hepatitis C virus. Clin Exp Immunol (2009) 1.04
Strain-specific T-cell suppression and protective immunity in patients with chronic hepatitis C virus infection. J Virol (2005) 1.03
Hepatic stellate cells preferentially induce Foxp3+ regulatory T cells by production of retinoic acid. J Immunol (2013) 1.02
Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C. Virulence (2012) 1.01
Hepatitis B Virus-Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. Gastroenterology (2015) 1.01
T-cell responses in hepatitis B and C virus infection: similarities and differences. Emerg Microbes Infect (2013) 1.00
Transient immunological control during acute hepatitis C virus infection: ex vivo analysis of helper T-cell responses. J Viral Hepat (2006) 1.00
Regulatory T cells in viral hepatitis. World J Gastroenterol (2007) 0.99
Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection. World J Gastroenterol (2007) 0.99
Suppression of HIV-specific and allogeneic T cell activation by human regulatory T cells is dependent on the strength of signals. PLoS One (2008) 0.97
Human leukocyte antigen class II associations with hepatitis C virus clearance and virus-specific CD4 T cell response among Caucasians and African Americans. Hepatology (2008) 0.97
Increased frequency of regulatory T cells and T lymphocyte activation in persons with previously treated extrapulmonary tuberculosis. Clin Vaccine Immunol (2011) 0.96
Regulatory T Cells, a Potent Immunoregulatory Target for CAM Researchers: Modulating Allergic and Infectious Disease Pathology (II). Evid Based Complement Alternat Med (2006) 0.94
CD4+ T cell responses in hepatitis C virus infection. World J Gastroenterol (2007) 0.93
The frequency of CD127(+) hepatitis C virus (HCV)-specific T cells but not the expression of exhaustion markers predicts the outcome of acute HCV infection. J Virol (2013) 0.93
T cells with regulatory activity in hepatitis C virus infection: what we know and what we don't. J Leukoc Biol (2008) 0.93
Foxp3 expression in liver correlates with the degree but not the cause of inflammation. Mediators Inflamm (2011) 0.92
Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol (2008) 0.92
HCV-HIV coinfection: simple messages from a complex disease. PLoS Med (2007) 0.91
Innate and Adaptive Immune Regulation During Chronic Viral Infections. Annu Rev Virol (2015) 0.89
Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment. J Transl Med (2010) 0.88
An insight into the diagnosis and pathogenesis of hepatitis C virus infection. World J Gastroenterol (2013) 0.87
CD4+ primary T cells expressing HCV-core protein upregulate Foxp3 and IL-10, suppressing CD4 and CD8 T cells. PLoS One (2014) 0.87
IL-2-independent and TNF-α-dependent expansion of Vβ5+ natural regulatory T cells during retrovirus infection. J Immunol (2013) 0.86
Adaptive immune response during hepatitis C virus infection. World J Gastroenterol (2014) 0.85
Hepatitis C virus induces regulatory T cells by naturally occurring viral variants to suppress T cell responses. Clin Dev Immunol (2010) 0.84
Role of host genetic factors in the outcome of hepatitis C virus infection. Viruses (2009) 0.84
Divergent contributions of regulatory T cells to the pathogenesis of chronic hepatitis C. Hum Vaccin Immunother (2013) 0.84
Induction of Multiple Immune Regulatory Pathways with Differential Impact in HCV/HIV Coinfection. Front Immunol (2014) 0.82
Ribavirin modulates the conversion of human CD4(+) CD25(-) T cell to CD4(+) CD25(+) FOXP3(+) T cell via suppressing interleukin-10-producing regulatory T cell. Immunology (2012) 0.82
T cell responses in hepatitis C virus infection: historical overview and goals for future research. Antiviral Res (2014) 0.82
Regulatory T Cells in Autoimmune and Viral Chronic Hepatitis. J Immunol Res (2015) 0.81
Smarter vaccine design will circumvent regulatory T cell-mediated evasion in chronic HIV and HCV infection. Front Microbiol (2014) 0.81
Regulatory T Cells Modulate DNA Vaccine Immunogenicity at Early Time via Functional CD4(+) T Cells and Antigen Duration. Front Immunol (2015) 0.81
T-cell dysfunction and inhibitory receptors in hepatitis C virus infection. Immune Netw (2010) 0.80
Viral interactions with B-cells contribute to increased regulatory T-cells during chronic HCV infection. Viral Immunol (2011) 0.79
A Mouse Model of Chronic West Nile Virus Disease. PLoS Pathog (2016) 0.79
Host-virus interactions in hepatitis B and hepatitis C infection. J Gastroenterol (2016) 0.79
Identification of CTL epitopes in hepatitis C virus by a genome-wide computational scanning and a rational design of peptide vaccine. Immunogenetics (2007) 0.79
Adaptive immunity in the liver. Cell Mol Immunol (2016) 0.78
Generation of T-cell receptors targeting a genetically stable and immunodominant cytotoxic T-lymphocyte epitope within hepatitis C virus non-structural protein 3. J Gen Virol (2011) 0.77
Immunopathogenesis of Hepatitis C Virus Infection. Gastroenterol Clin North Am (2015) 0.77
Elevated frequency and function of regulatory T cells in patients with active chronic hepatitis C. J Gastroenterol (2012) 0.77
Impact of oral silymarin on virus- and non-virus-specific T-cell responses in chronic hepatitis C infection. J Viral Hepat (2013) 0.77
Indoleamine 2,3-dioxygenase expression and activity in patients with hepatitis C virus-induced liver cirrhosis. Exp Ther Med (2014) 0.77
Identifying protective Streptococcus pyogenes vaccine antigens recognized by both B and T cells in human adults and children. Sci Rep (2016) 0.76
New Mechanism of Hepatic Fibrogenesis: Hepatitis C Virus Infection Induces Transforming Growth Factor β1 Production through Glucose-Regulated Protein 94. J Virol (2015) 0.76
Immune and non-immune responses to hepatitis C virus infection. World J Gastroenterol (2015) 0.76
Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients. J Gastroenterol (2011) 0.76
Between Scylla and Charybdis: the role of the human immune system in the pathogenesis of hepatitis C. World J Gastroenterol (2013) 0.76
Overexpression of Regulatory T Cells Type 1 (Tr1) Specific Markers in a Patient with HCV-Induced Hepatocellular Carcinoma. ISRN Hepatol (2013) 0.76
Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patients. Arch Virol (2016) 0.75
Phenotypic Characteristics of PD-1 and CTLA-4 Expression in Symptomatic Acute Hepatitis A. Gut Liver (2016) 0.75
Regulatory T Cells in Hepatitis B and C Virus Infections. Immune Netw (2016) 0.75
Modulation of Hepatitis C Virus-Specific CD8 Effector T-Cell Function with Antiviral Effect in Infectious Hepatitis C Virus Coculture Model. J Virol (2017) 0.75
Progress in the development of vaccines for hepatitis C virus infection. World J Gastroenterol (2015) 0.75
Prediction of antiviral efficacy in patients with chronic hepatitis C by changes in forkhead box protein 3 levels. Exp Ther Med (2014) 0.75
Cellular immune response to hepatitis-C-virus in subjects without viremia or seroconversion: is it important? Infect Agent Cancer (2016) 0.75
Methodologies for the Analysis of HCV-Specific CD4(+) T Cells. Front Immunol (2015) 0.75
The Immune Fulcrum: Regulatory T Cells Tip the Balance Between Pro- and Anti-inflammatory Outcomes upon Infection. Prog Mol Biol Transl Sci (2015) 0.75
Adaptive immunity to hepatitis C virus. Viruses (2009) 0.75
Cellular immune responses against persistent hepatitis C virus: gone but not forgotten. Gut (2006) 0.75
CD4(+) T-cell engagement by both wild-type and variant HCV peptides modulates the conversion of viral clearing helper T cells to Tregs. Future Virol (2013) 0.75
Quantitative assessment of serum NV-F virus DNA concentrations in samples from patients coinfected with hepatitis B or C virus. J Clin Microbiol (2006) 0.75
Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection. Vaccines (Basel) (2017) 0.75
Capturing the systemic immune signature of a norovirus infection: an n-of-1 case study within a clinical trial. Wellcome Open Res (2017) 0.75
Retracted Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors. Proc Natl Acad Sci U S A (2010) 4.31
Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science (2012) 4.20
Rare birds in North America: acute hepatitis C cohorts. Gastroenterology (2008) 3.45
Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol (2005) 3.09
Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology (2008) 2.95
Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog (2009) 2.57
Hepatitis C virus transmission bottlenecks analyzed by deep sequencing. J Virol (2010) 2.45
Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (2013) 2.17
Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology (2006) 2.05
Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci U S A (2002) 2.04
A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A (2002) 2.02
Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc Natl Acad Sci U S A (2008) 1.82
Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci U S A (2009) 1.72
Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci U S A (2007) 1.66
Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection. J Virol (2008) 1.63
Investigation of residual hepatitis C virus in presumed recovered subjects. Hepatology (2012) 1.61
Absence of transfusion-associated microchimerism in pediatric and adult recipients of leukoreduced and gamma-irradiated blood components. Transfusion (2011) 1.59
Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science (2011) 1.56
Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology (2004) 1.49
Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid. J Gastroenterol Hepatol (2011) 1.49
Serum levels of platelet-derived growth factor-BB and vascular endothelial growth factor as prognostic factors for patients with fulminant hepatic failure. J Gastroenterol Hepatol (2011) 1.45
Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur J Immunol (2012) 1.41
HCV natural history: the retrospective and prospective in perspective. J Hepatol (2005) 1.40
Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology (2003) 1.39
Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity. Hepatology (2005) 1.38
An assessment of hepatitis E virus (HEV) in US blood donors and recipients: no detectable HEV RNA in 1939 donors tested and no evidence for HEV transmission to 362 prospectively followed recipients. Transfusion (2013) 1.36
Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology (2003) 1.34
Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J Virol (2008) 1.33
Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology (2006) 1.31
Racial differences in hepatitis C treatment eligibility. Hepatology (2011) 1.28
Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci U S A (2003) 1.26
A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci U S A (2007) 1.24
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat (2014) 1.23
Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis. J Hepatol (2008) 1.22
Frequency and duration of plasma CMV viremia in seroconverting blood donors and recipients. Transfusion (2003) 1.19
Inflammatory fibroid polyp occurring in the transverse colon diagnosed by endoscopic biopsy. World J Gastroenterol (2007) 1.18
Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated aplastic anemia, or acute and chronic non-A-E hepatitis. J Infect Dis (2003) 1.18
Hepatitis C: the end of the beginning and possibly the beginning of the end. Ann Intern Med (2012) 1.18
Highly quantitative serological detection of anti-cytomegalovirus (CMV) antibodies. Virol J (2009) 1.17
Hepatitis C virus: virology and life cycle. Clin Mol Hepatol (2013) 1.15
Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. Proc Natl Acad Sci U S A (2006) 1.11
Three cases of Solitary Peutz-Jeghers-type hamartomatous polyp in the duodenum. World J Gastroenterol (2008) 1.10
Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. J Gastroenterol Hepatol (2011) 1.10
Genomic scale analysis of racial impact on response to IFN-alpha. Proc Natl Acad Sci U S A (2009) 1.08
Homeostasis of peripheral FoxP3(+) CD4 (+) regulatory T cells in patients with early and late stage breast cancer. Cancer Immunol Immunother (2009) 1.07
T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C. Hepatology (2005) 1.04
Observation of positive selection within hypervariable regions of a newly identified DNA virus (SEN virus)(1). FEBS Lett (2002) 1.04
Strain-specific T-cell suppression and protective immunity in patients with chronic hepatitis C virus infection. J Virol (2005) 1.03
Clinical spectrum and histopathologic features of chronic hepatitis C infection in children. J Pediatr (2007) 1.01
Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis. Proc Natl Acad Sci U S A (2012) 1.01
Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion (2005) 1.00
Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. Clin Cancer Res (2009) 1.00
Treatment of over 20 mm gastric cancer by endoscopic submucosal dissection using an insulation-tipped diathermic knife. World J Gastroenterol (2007) 0.98
Human leukocyte antigen class II associations with hepatitis C virus clearance and virus-specific CD4 T cell response among Caucasians and African Americans. Hepatology (2008) 0.97
SEN virus: epidemiology and characteristics of a transfusion-transmitted virus. Transfusion (2005) 0.97
Neutralization epitope responsible for the hepatitis B virus subtype-specific protection in chimpanzees. Proc Natl Acad Sci U S A (2006) 0.97
Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-positive B-cell population. Hepatology (2012) 0.93
SEN virus: response to interferon alfa and influence on the severity and treatment response of coexistent hepatitis C. Hepatology (2002) 0.93
Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine. Hepatol Res (2011) 0.93
Evolutionary analysis of hepatitis C virus gene sequences from 1953. Philos Trans R Soc Lond B Biol Sci (2013) 0.92
Racial difference in mortality among U.S. veterans with HCV/HIV coinfection. Am J Gastroenterol (2006) 0.92
The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis. J Gastroenterol (2012) 0.91
Towards a molecular understanding of the differential signals regulating alphabeta/gammadelta T lineage choice. Semin Immunol (2010) 0.91
Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes. J Gen Virol (2004) 0.90
A 25-year study of the clinical and histologic outcomes of hepatitis C virus infection and its modes of transmission in a cohort of initially asymptomatic blood donors. J Infect Dis (2012) 0.90
Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma. J Gastroenterol (2011) 0.90
Retraction for Lo et al., Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors. Proc Natl Acad Sci U S A (2011) 0.90
Serum glycan markers for evaluation of disease activity and prediction of clinical course in patients with ulcerative colitis. PLoS One (2013) 0.89
Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein. J Gastroenterol Hepatol (2011) 0.89
Association of interleukin-15-induced peripheral immune activation with hepatic stellate cell activation in persons coinfected with hepatitis C virus and HIV. J Infect Dis (2009) 0.88
Prospective study of hepatitis C viral infection as a risk factor for subsequent B-cell neoplasia. Blood (2002) 0.88
Parvovirus B19 infection transmitted by transfusion of red blood cells confirmed by molecular analysis of linked donor and recipient samples. Transfusion (2010) 0.88
Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer. J Gastroenterol (2013) 0.87
Quantitative analysis of anti-hepatitis C virus antibody-secreting B cells in patients with chronic hepatitis C. Hepatology (2006) 0.87
Clinical features of antinuclear antibodies-negative type 1 autoimmune hepatitis. Hepatol Res (2008) 0.87
Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA. Immunology (2007) 0.87
Evaluation of the effect of sorafenib using serum NX-des-γ-carboxyprothrombin in patients with hepatocellular carcinoma. Hepatol Res (2013) 0.86
Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 by cationic liposome encapsulated DNA immunization. Hepatology (2003) 0.86
Which patients respond best to hepatitis B vaccination after a hepatitis B virus-related liver transplantation? J Gastroenterol (2013) 0.86
The clinical relevance of persistent recombinant immunoblot assay-indeterminate reactions: insights into the natural history of hepatitis C virus infection and implications for donor counseling. Transfusion (2012) 0.85
+49A/G polymorphism of cytotoxic T-lymphocyte antigen 4 gene in type 1 autoimmune hepatitis and primary biliary cirrhosis: A meta-analysis. Hepatol Res (2011) 0.85
Clinical features of autoimmune hepatitis diagnosed based on simplified criteria of the International Autoimmune Hepatitis Group. Dig Liver Dis (2009) 0.85
Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma. Hepatol Res (2013) 0.85
A view to natural killer cells in hepatitis C. Gastroenterology (2011) 0.85
A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients. J Clin Psychiatry (2003) 0.84